Arrow-right Camera
The Spokesman-Review Newspaper
Spokane, Washington  Est. May 19, 1883

EpiPen manufacturer will be a no-show at Senate hearing

In this July 8 file photo, a pharmacist holds a package of EpiPen epinephrine auto-injectors, a Mylan product, in Sacramento, Calif. (Rich Pedroncelli / Associated Press)
By Mary Clare Jalonick Associated Press

WASHINGTON – Senate Judiciary Chairman Charles Grassley says pharmaceutical company Mylan is declining to testify at his committee’s hearing next week on a settlement between the company and the Justice Department over its life-saving Epi-Pen.

Grassley on Monday released a letter from an attorney for Mylan saying officials would not testify. The Nov. 18 letter said company executives wouldn’t testify because the settlement is a pending matter and the Justice Department would also not be attending.

Mylan will pay $465 million to settle allegations that it overbilled Medicaid for EpiPen. At issue was whether the product should have been classified as generic under a Medicaid program.

The list price of EpiPens had grown to $608 for a two-pack, an increase of more than 500 percent since 2007.